(Q36344344)

13 August 2017

title

Clinical assessment of spasticity in children with cerebral palsy: a critical review of available instruments (English)

1 reference

13 August 2017

1 reference

1 reference

Vanessa A B Scholtes

1

1 reference

13 August 2017

Jules G Becher

series ordinal

2

1 reference

13 August 2017

Anita Beelen

series ordinal

3

1 reference

13 August 2017

Gustaaf J Lankhorst

series ordinal

4

1 reference

13 August 2017

publication date

1 January 2006

1 reference

Developmental Medicine and Child Neurology

13 August 2017

published in

1 reference

13 August 2017

volume

48

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

64-73

1 reference

Recommendations for the use of botulinum toxin type A in the management of cerebral palsy.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Spasticity versus strength in cerebral palsy: relationships among involuntary resistance, voluntary torque, and motor function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Classification and definition of disorders causing hypertonia in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Spasticity: clinical perceptions, neurological realities and meaningful measurement

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Quantitative analysis of the velocity related pathophysiology of spasticity and rigidity in the elbow flexors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

The pathophysiology of spasticity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Influence of learning to read and write on the morphology of the corpus callosum

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Relief of hemiparetic spasticity by TENS is associated with improvement in reflex and voluntary motor functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Relationships among musculoskeletal impairments and functional health status in ambulatory cerebral palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Botulinum toxin A in hamstring spasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Outcome measures of spasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Selective posterior rhizotomy for lower extremity spasticity: how much and which of the posterior rootlets should be cut?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Intrathecal baclofen therapy in children with cerebral palsy: efficacy and complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

The effect of intrathecal baclofen on muscle co-contraction in children with spasticity of cerebral origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Changes in movement characteristics of the spastic upper extremity after botulinum toxin injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Motor control testing of upper limb function after botulinum toxin injection: a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Effects of Johnstone pressure splints combined with neurodevelopmental therapy on spasticity and cutaneous sensory inputs in spastic cerebral palsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Medium-term functional benefits in children with cerebral palsy treated with botulinum toxin type A: 1-year follow-up using gross motor function measure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

The effect of spasticity on cortical somatosensory-evoked potentials: changes of cortical somatosensory-evoked potentials after botulinum toxin type A injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Continuous intrathecal baclofen infusion for children with cerebral palsy: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Functional improvement in cerebral palsy patients treated with botulinum toxin A injections - preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Outcomes after selective dorsal rhizotomy for spastic cerebral palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Spastic velocity threshold constrains functional performance in cerebral palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Reversible F-wave hyperexcitability associated with antibodies to potassium channels in Isaacs' syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Demonstration of delayed recovery from fatiguing exercise in chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Developmental skills of children with spastic diplegia: functional and qualitative changes after selective dorsal rhizotomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Botulinum toxin A in management of cerebral palsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Functional assessment of children with cerebral palsy following limited (L4-S1) selective posterior rhizotomy--a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Selective dorsal rhizotomy as a treatment option for children with spastic cerebral palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Selective musculocutaneous fasciculotomy for spastic elbow in cerebral palsy: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

A simulation study of reflex instability in spasticity: origins of clonus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

Cerebral Palsy Epidemiology: Where are We Now and Where are We Going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Baclofen in the treatment of cerebral palsy.

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Spasticity in cerebral palsy and the selective posterior rhizotomy procedure

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Response to stretch of hypertonic muscle groups in hemiplegia

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

The role of stretch reflex threshold regulation in normal and impaired motor control

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

The importance of posture on the isokinetic assessment of spasticity

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Clinical method of assessing tonus and voluntary movement in hemiplegia.

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Interrater reliability of a modified Ashworth scale of muscle spasticity

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Functional outcomes following selective posterior rhizotomy in children with cerebral palsy

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Microsurgical DREZ-otomy for the treatment of spasticity and pain in the lower limbs

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Intrathecal baclofen for spasticity in cerebral palsy

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Effects of continuous intrathecal baclofen infusion and selective posterior rhizotomy on upper extremity spasticity

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Multidimensional assessment of motor function in a child with cerebral palsy following intrathecal administration of baclofen

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Functional assessment following intrathecal baclofen therapy in children with spastic cerebral palsy

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

[Spasticity and dynamic plantar pressure distribution measurements in hemiplegic spastic children]

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

"Extensor toe sign" by various methods in spastic children with cerebral palsy

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Intrathecal baclofen for management of spastic cerebral palsy: multicenter trial

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Botulinum toxin for spasticity and athetosis in children with cerebral palsy

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Selective posterior rhizotomy in children with cerebral palsy: a 10-year experience

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Intrathecal baclofen for motor disorders

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

The use of botulinum toxin type A treatment in children with spasticity

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Intrathecal baclofen for intractable cerebral spasticity: a prospective placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Spasticity in children with cerebral palsy: a retrospective review of the effects of intrathecal baclofen

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of "high-dose" versus "low-dose" treatment

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Use of botulinum toxin injection in 17 children with spastic cerebral palsy

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Open-label study of botulinum toxin for upper limb spasticity in cerebral palsy

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

[Some practice-relevant aspects of the pharmacokinetics of THC]

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Botulinum toxin and short-term electrical stimulation in the treatment of equinus in cerebral palsy

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Parameters for predicting favorable responses to botulinum toxin in children with cerebral palsy

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Botulinum toxin type A injections in the spastic upper extremity of children with hemiplegia: child characteristics that predict a positive outcome

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Impairment, disability, and satisfaction outcomes after lower-extremity botulinum toxin a injections for children with cerebral palsy

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Effects of botulinum toxin A on upper limb spasticity in children with cerebral palsy

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Long-term outcome after selective posterior rhizotomy in children with spastic cerebral palsy

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Electrophysiological monitoring during selective dorsal rhizotomy, and spasticity and GMFM performance

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Adductor spasticity in children with cerebral palsy and treatment with botulinum toxin type A: the parents' view of functional outcome

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Physical management of spasticity

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Use of modafinil in spastic cerebral palsy

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Follow-up of children with cerebral palsy after selective posterior rhizotomy with intensive physiotherapy or physiotherapy alone

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Evaluation of botulinum toxin A therapy in children with adductor spasm by gross motor function measure

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Treatment of cerebral palsy with botulinum toxin A: functional benefit and reduction of disability. Three case reports

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Oxygen cost, walking speed, and perceived exertion in children with cerebral palsy when walking with anterior and posterior walkers

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Selective dorsal rhizotomy: efficacy and safety in an investigator-masked randomized clinical trial

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

The role of selective dorsal rhizotomy in cerebral palsy: critical evaluation of a prospective clinical series

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Nonselective partial dorsal rhizotomy: a clinical experience with 1-year follow-Up

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

A randomized clinical trial to compare selective posterior rhizotomy plus physiotherapy with physiotherapy alone in children with spastic diplegic cerebral palsy

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Comparison of motor outcomes after selective dorsal rhizotomy with and without preoperative intensified physiotherapy in children with spastic diplegic cerebral palsy

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Managing spasticity in pediatric cerebral palsy using a very low dose of botulinum toxin type A: preliminary report

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Gait changes in children with spastic diplegia after selective dorsal rhizotomy

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Evaluation of selective dorsal rhizotomy for the reduction of spasticity in cerebral palsy: a randomized controlled tria

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Orthopedic procedures after rhizotomy

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Nerve rootlets to be sectioned for spasticity resolution in selective dorsal rhizotomy

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Intrathecally administered baclofen for treatment of children with spasticity of cerebral origin.

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Long-term functional outcome after selective posterior rhizotomy

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Residual spasticity after selective posterior rhizotomy

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Limited (L4-S1, L5-S1) selective dorsal rhizotomy for reducing spasticity in cerebral palsy

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Limited selective posterior rhizotomy for the treatment of spasticity secondary to infantile cerebral palsy: a preliminary report

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

Selective dorsal rhizotomy in children with cerebral palsy. Results in 18 cases at one year postoperatively

1 reference

https://api.crossref.org/works/10.1017%2FS0012162206000132

7 January 2021

10.1017/S0012162206000132

Identifiers

DOI

1 reference

13 August 2017

1 reference